Search Press releases Keywords From To Category Therapy AreasAxial spondyloarthritisChronic inflammatory demyelinating polyneuropathyCrohn's diseaseEpilepsyHidradenitis suppurativaImmune ThrombocytopeniaImmune-mediated necrotizing myopathyLupusMyasthenia gravisOsteoporosisParkinson's diseaseProgressive supranuclear palsyPsoriasisPsoriatic arthritisRestless legs syndromeRheumatoid Arthritis TopicCorporateFinancialsPartnershipsPipeline progressResearch UCB MedicinesbimekizumabBriviactCimziaEvenityNayzilamNeuproVimpat 31 Jan 2003 UCB closes on its acquisition of Solutia's Resins, Additives and Adhesives businesses Read More 22 Jan 2003 UCB : Fourth quarter year-to-date Zyrtec sales in the US increase by 13%. Read More 14 Jan 2003 UCB: Acquisition in the field of Specialty Chemicals Read More Pagination First page Previous page Previous … Page 185 Page 186 Page 187 Page 188 Page 189 Page 190 Page 191 Page 192 Current page 193 Stay up-to-date on the latest news and information from UCB Subscribe